Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II study of sargramostim added to D-VCD in untreated AL amyloidosis
2021-005769-42Phase 2Active
- Sponsor
- Medical University of Warsaw
- Start
- Mar 2022
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, single-arm trial of sargramostim in light-chain amyloidosis, sponsored by Medical University of Warsaw. Started Mar 2022; status: active.
02
Drugs
sargramostim
03
Conditions
light-chain amyloidosis
Beyond the preview
Go deeper on 2021-005769-42.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-005769-42.